

# By the Patients You Treat

## Program Title

A Closer Look at the Treatment and Toxicity Management for ALL

## Program Description

Shire would like to personally invite you to a special presentation on ONCASPAR® (pegaspargase). This live session will provide a unique opportunity to interact with your peers and our guest speaker in a facilitated discussion about the distinct needs and treatment of patients with acute lymphoblastic leukemia (ALL).

### Presenter

#### Bernard Marini, PharmD

Clinical Pharmacist Specialist, Hematology,  
Adjunct Clinical Assistant Professor University of  
Michigan Health System

### Program Information

#### Date

Wednesday, August 23, 2017

#### Time

5:30-8:30 PM

#### Venue and Address

Alexander's Steakhouse  
19379 Stevens Creek Blvd,  
Cupertino, CA 95014  
(408) 446-2222

## RSVP Deadline

Friday, August 18, 2017

Please contact your Shire representative, Christopher Greig,  
at [christopher.greig@shire.com](mailto:christopher.greig@shire.com) or (650) 380-8934, if you would like to attend this  
program.

This is a non-CME event sponsored by Shire. In accordance with state laws, we are prohibited from providing meals and food items to healthcare professionals licensed or practicing in the states of Minnesota and Vermont. Invited participants may not bring guests. Shire will collect and report healthcare professional information concerning meals and other transfers of value pursuant to the Federal Sunshine Act and state laws.

## ONCASPAR (pegaspargase)

### Indication and Usage

ONCASPAR (pegaspargase) is indicated as a component of multi-agent chemotherapeutic regimen for treatment of patients with:

- First-line Acute Lymphoblastic Leukemia (ALL)
- ALL and hypersensitivity to native forms of L-asparaginase.

Please see ONCASPAR Detailed Important Safety Information on the following page.



## Detailed Important Safety Information

### CONTRAINDICATIONS

- History of serious allergic reactions to ONCASPAR
- History of serious thrombosis with prior L-asparaginase therapy
- History of pancreatitis with prior L-asparaginase therapy
- History of serious hemorrhagic events with prior L-asparaginase therapy

### WARNINGS and PRECAUTIONS

**Anaphylaxis and Serious Allergic Reactions:** Anaphylaxis or serious allergic reactions can occur; therefore, patients should be observed for one hour after administration. Discontinue ONCASPAR in patients with serious allergic reactions.

**Thrombosis:** Serious thrombotic events, including sagittal sinus thrombosis can occur. Discontinue ONCASPAR in patients with serious thrombotic events

**Pancreatitis:** Pancreatitis can occur. Evaluate patients with abdominal pain for evidence of pancreatitis. Discontinue ONCASPAR in patients with pancreatitis

**Glucose Intolerance:** Glucose intolerance can occur. In some cases, glucose intolerance is irreversible. Monitor serum glucose.

**Coagulopathy:** Increased prothrombin time, increased partial thromboplastin time, and hypofibrinogenemia can occur. Monitor coagulation parameters at baseline and periodically during and after treatment.

**Hepatotoxicity:** Hepatotoxicity and abnormal liver function, can occur. Perform appropriate monitoring.

### ADVERSE REACTIONS

The most common adverse reactions with ONCASPAR ( $\geq 2\%$ ) are allergic reactions (including anaphylaxis), hyperglycemia, pancreatitis, central nervous system (CNS) thrombosis, coagulopathy, hyperbilirubinemia, and elevated transaminases.

Hyperlipidemia (hypercholesterolemia and hypertriglyceridemia) has been reported in patients exposed to ONCASPAR.

**Please see the accompanying Full Prescribing Information.**